Bristol Myers Squibb: Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
25.08.2023 - The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today presented results from ATHENS, a retrospective real-world data study, at the European Society of Cardiology (ESC) Congress 2023 showing that switching from Eliquis .
New analyses, including late-breaking data and presentations on CAMZYOS® and Eliquis® , reaffirm the company s steadfast dedication to tackling cardiovascular diseases
.